Daniel Brennan
Stock Analyst at TD Cowen
(1.71)
# 3,433
Out of 5,140 analysts
20
Total ratings
33.33%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $7.05 | +126.95% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $1.64 | +52.44% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $12.21 | +137.51% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $2.42 | +3.31% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $613 → $670 | $636.30 | +5.30% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $226.77 | -11.80% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,442.93 | -46.64% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $102.48 | +12.22% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $7.05
Upside: +126.95%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $1.64
Upside: +52.44%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $12.21
Upside: +137.51%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $2.42
Upside: +3.31%
Thermo Fisher Scientific
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $636.30
Upside: +5.30%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $226.77
Upside: -11.80%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,442.93
Upside: -46.64%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $102.48
Upside: +12.22%